TY - JOUR T1 - A cluster randomised trial of the impact of a policy of daily testing for contacts of COVID-19 cases on attendance and COVID-19 transmission in English secondary schools and colleges JF - medRxiv DO - 10.1101/2021.07.23.21260992 SP - 2021.07.23.21260992 AU - Bernadette C Young AU - David W Eyre AU - Saroj Kendrick AU - Chris White AU - Sylvester Smith AU - George Beveridge AU - Toby Nonnemacher AU - Fegor Ichofu AU - Joseph Hillier AU - Ian Diamond AU - Emma Rourke AU - Fiona Dawe AU - Ieuan Day AU - Lisa Davies AU - Paul Staite AU - Andrea Lacey AU - James McCrae AU - Ffion Jones AU - Joseph Kelly AU - Urszula Bankiewicz AU - Sarah Tunkel AU - Richard Ovens AU - David Chapman AU - Peter Marks AU - Nick Hicks AU - Tom Fowler AU - Susan Hopkins AU - Lucy Yardley AU - Tim EA Peto Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/25/2021.07.23.21260992.abstract N2 - Background School-based COVID-19 contacts in England are asked to self-isolate at home. However, this has led to large numbers of missed school days. Therefore, we trialled daily testing of contacts as an alternative, to investigate if it would affect transmission in schools.Methods We performed an open-label cluster randomised controlled trial in students and staff from secondary schools and further education colleges in England (ISRCTN18100261). Schools were randomised to self-isolation of COVID-19 contacts for 10 days (control) or to voluntary daily lateral flow device (LFD) testing for school contacts with LFD-negative contacts remaining at school (intervention). Household contacts were excluded from participation.Co-primary outcomes in all students and staff were symptomatic COVID-19, adjusted for community case rates, to estimate within-school transmission (non-inferiority margin: <50% relative increase), and COVID-19-related school absence. Analyses were performed on an intention to treat (ITT) basis using quasi-Poisson regression, also estimating complier average causal effects (CACE). Secondary outcomes included participation rates, PCR results in contacts and performance characteristics of LFDs vs. PCR.Findings Of 99 control and 102 intervention schools, 76 and 86 actively participated (19-April-2021 to 27-June-2021); additional national data allowed most non-participating schools to be included in the co-primary outcomes. 2432/5763(42.4%) intervention arm contacts participated. There were 657 symptomatic PCR-confirmed infections during 7,782,537 days-at-risk (59.1/100k/week) and 740 during 8,379,749 days-at-risk (61.8/100k/week) in the control and intervention arms respectively (ITT adjusted incidence rate ratio, aIRR=0.96 [95%CI 0.75-1.22;p=0.72]) (CACE-aIRR=0.86 [0.55-1.34]). There were 55,718 COVID-related absences during 3,092,515 person-school-days (1.8%) and 48,609 during 3,305,403 person-school-days(1.5%) in the control and intervention arms (ITT-aIRR=0.80 [95%CI 0.53-1.21;p=0.29]) (CACE-aIRR 0.61 [0.30-1.23]). 14/886(1.6%) control contacts providing an asymptomatic PCR sample tested positive compared to 44/2981(1.5%) intervention contacts (adjusted odds ratio, aOR=0.73 [95%CI 0.33-1.61;p=0.44]). Rates of symptomatic infection in contacts were 44/4665(0.9%) and 79/5955(1.3%), respectively (aOR=1.21 [0.82-1.79;p=0.34]).Interpretation Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission. COVID-19 rates in school-based contacts in both intervention and control groups were <2%. Daily contact testing is a safe alternative to home isolation following school-based exposures.Competing Interest StatementDWE reports lecture fees from Gilead outside the submitted work. RO and DC are consultants employed by DHSC as part of Deloitte's broader project work supporting the delivery of NHS Test and Trace. TF reports honoraria from Qatar National Research Fund (QNRF) outside the submitted work, no other author has a conflict of interest to declare.Clinical TrialISRCTN18100261Funding StatementThis study was funded by the UK Government Department of Health and Social Care and supported by the UK Government Department for Education and Office for National Statistics. The work was also supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) (NIHR200915) and the NIHR Biomedical Research Centre, Oxford. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care, the Department for Education, the Office for National Statistics or Public Health England. BCY is an NIHR clinical lecturer. BCY, TEAP and LY received grants from DHSC to fund this work. DWE is a Robertson Foundation Fellow.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and ethical approved granted by Public Health England's Research Ethics and Governance Group (ref R&D 434). The study was done in accordance with the Declaration of Helsinki and national legislation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the trial will be available within the Office for National Statistics Secure Research Service. Applications for access can be made by Accredited Researchers. For more details please see - https://cy.ons.gov.uk/aboutus/whatwedo/statistics/requestingstatistics/approvedresearcherscheme. ER -